Live In-Person or Virtual
Shifting the PAH Paradigm: Early Detection, Treatment Escalation Strategies, and Novel Therapies
Event Date
Wednesday, Oct 22, 2025
Event Time
6:00 AM Central
Location
Chicago or Virtual
Estimated Time to Complete Activity
1.25 hrs.
Specialty
Administration, Allergy & Immunology, Cardiology, Education, Geriatric Medicine, Primary Care, Pulmonology
Topics
Acute Heart Failure, Allergies, Cardiovascular Disease, Geriatric Medicine, Heart, Pharmacology
This activity is provided by Prime.
Credit Available
- 1.25 CME/CE for Physicians (ACCME)
- 1.25 CME/CE for Physicians Assistants (AAPA)
- 1.25 CH/CE for Nurse Practitioners (AANP)
- 1.25 CPE for Pharmacists (ACPE + NABP)
- 1.25 CNE for Nurses (ANCC)
Program Overview
Intended Audience: Pulmonologists, Cardiologists, Allergists/Immunologists and their clinical care teams of advanced practice providers (NPs, PAs), nurses, and pharmacists
Pulmonary arterial hypertension (PAH) remains a progressive, life-threatening disease marked by nonspecific symptoms, diagnostic delays, and complex treatment pathways. The recent emergence of novel therapies and ever-evolving clinical guidance offers a renewed opportunity to transform patient outcomes through earlier detection and timely treatment escalation with evidence-based combination regimens.
Join this dynamic live symposium, where two renowned PAH experts will lead participants through interactive case-based discussions centered on the latest clinical evidence, updated guidelines, and practical approaches to optimizing care. Through illustrative video animations, live audience polling, real-world clinical case challenges, and live Q&A with expert faculty, participants will gain actionable insights into identifying patients earlier in the disease course, applying goal-oriented treatment strategies, navigating timely treatment escalation, and integrating new therapies into personalized treatment plans.
Attendees will leave equipped with the knowledge to deliver individualized, evidence-based care, and will receive first-hand access to a practical point-of-care PAH guide to support clinical decision-making.
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.
Learning Objectives
- Describe pathophysiologic pathways involved in the development of PAH, including the role of vascular and right ventricle remodeling in disease progression
- Incorporate guideline-recommended approaches for PAH diagnosis and treatment, including risk stratification and appropriate use of multi-drug regimens
- Evaluate the latest clinical trial data on the safety and efficacy of novel therapies for PAH
- Apply goal-oriented strategies to inform decisions on when and how to escalate therapy, including guideline-directed use of combination therapy
Faculty
Jeremy Feldman, MD, FCCP
Speaker
Director, Pulmonary Hypertension Program
Medical Director, High Risk Care
Sonja Bartolome, M.D.
Speaker
Director, Pulmonary Vascular Disease Program
Professor, Internal Medicine, Pulmonary and Critical Care
UT Southwestern
Dallas, TX
Ryan J. Atkinson, PharmD, MBA
Moderator
Vice President, Payer Contracting
Amber Specialty Pharmacy